Cancer treatment has entered a new era in which understanding the biological characteristics of a tumour is becoming increasingly important. Traditional cancer treatment approaches often rely on cancer type, stage, and other clinical characteristics. However, advances in molecular biology, genetic sequencing, and diagnostic technologies are helping oncologists make more personalised treatment decisions. This approach, known as precision oncology, is changing how healthcare professionals understand and manage different types of cancer.

Through ongoing research, clinical trials, and expert discussions, ONC Brothers helps bridge the gap between academic oncology research and community cancer care. Its educational resources explore emerging treatment strategies, clinical evidence, and developments that can help healthcare professionals stay informed about the evolving cancer treatment landscape.

Understanding Precision Oncology in Modern Cancer Care

Precision oncology is an approach to cancer treatment that considers the genetic, molecular, and biological characteristics of an individual's tumour. Rather than assuming that every patient with the same cancer diagnosis will respond identically, oncologists evaluate specific tumour features that may influence treatment effectiveness.

Cancer develops through changes in cellular DNA and other biological processes. These alterations can affect how cancer cells grow, divide, spread, and respond to treatment. Identifying relevant genetic mutations, protein expressions, and molecular pathways can help specialists determine whether certain targeted therapies or immunotherapies may be appropriate.

For example, specific genetic alterations in non-small cell lung cancer can influence treatment selection. Similarly, HER2 expression and mutations may provide important information when evaluating treatment options for certain breast, gastric, and lung cancers.

These developments demonstrate why personalised cancer treatment has become an important area of modern oncology research.

The Importance of Biomarker Testing in Cancer Treatment

Biomarker testing plays a central role in precision medicine. It involves analysing tumour tissue, blood samples, or other biological materials to identify characteristics that may provide useful information about a patient's cancer.

Common biomarkers include:

• Genetic mutations and alterations.

• Protein expression levels.

• Gene rearrangements and fusions.

• Microsatellite instability (MSI).

• Tumour mutational burden (TMB).

• Hormone receptor expression.

Doctors may use different testing methods depending on the cancer type and clinical situation. These include immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS).

Next-generation sequencing is particularly valuable because it can examine multiple genetic alterations within a tumour using a single testing approach. This information may identify potential treatment targets and, in selected circumstances, clinical trial opportunities.

However, not every biomarker has an established treatment option. Test results must be interpreted alongside clinical findings, tumour characteristics, available evidence, and the patient's overall health.

How Targeted Therapy Is Changing Cancer Management

Targeted therapy is one of the most important developments associated with precision oncology. These treatments are designed to interfere with specific proteins or molecular pathways involved in cancer cell growth and survival.

Unlike conventional chemotherapy, which can affect rapidly dividing healthy and cancerous cells, targeted treatments focus on particular biological mechanisms. This does not mean they are free from side effects, but their mechanisms of action differ from traditional chemotherapy.

Examples include EGFR inhibitors for certain EGFR-mutated lung cancers and HER2-directed therapies for eligible HER2-positive cancers.

The development of targeted treatments has also increased the importance of molecular diagnostics. Before selecting a biomarker-directed treatment, healthcare professionals need to determine whether the relevant molecular target is present and whether the available therapy is appropriate.

Researchers continue to investigate new molecular targets, drug combinations, resistance mechanisms, and treatment sequences to improve outcomes across different cancer types.

HER2 Testing and Its Growing Role in Oncology

HER2 is a protein involved in cell growth and development. In certain cancers, increased HER2 expression or specific HER2 gene alterations can contribute to tumour progression.

HER2 testing is particularly important in breast and gastric cancer, while researchers are also exploring its significance in other tumour types, including non-small cell lung cancer.

Modern diagnostic methods help distinguish between HER2 overexpression, gene amplification, and HER2 mutations. These differences matter because treatment eligibility and therapeutic approaches can vary depending on the biological findings.

Antibody-drug conjugates represent another important advancement in HER2-directed cancer treatment. These medicines combine an antibody that recognises a particular tumour-associated target with a linked cytotoxic drug. Their purpose is to deliver treatment more selectively, although careful monitoring is still necessary because significant adverse effects can occur.

Healthcare professionals interested in the evolving diagnostic and therapeutic landscape can explore HER2-positive NSCLC testing and treatment insights, including discussions about next-generation sequencing, biomarker evaluation, and treatment-related toxicities.

Immunotherapy and the Role of the Immune System

Immunotherapy has become an important treatment option for several types of cancer. Unlike targeted therapies that act on particular molecular pathways, certain immunotherapies help the body's immune system recognise and attack cancer cells.

Immune checkpoint inhibitors are a well-established example. They target proteins such as PD-1, PD-L1, and CTLA-4, which are involved in regulating immune responses.

In selected patients, immunotherapy can produce meaningful and sometimes durable responses. However, its effectiveness varies according to cancer type, biomarker status, disease characteristics, and individual patient factors.

Researchers are investigating combinations of immunotherapy with chemotherapy, targeted treatments, radiation therapy, and other therapeutic approaches. These studies aim to identify which combinations provide meaningful benefits while maintaining manageable safety profiles.

The Importance of Clinical Research and Oncology Education

Cancer research continuously generates new evidence that can influence clinical practice. Large oncology conferences, peer-reviewed publications, and clinical trials provide opportunities to evaluate emerging treatments and understand how scientific findings may translate into patient care.

However, new research findings do not automatically become standard treatment recommendations. Clinical evidence must be evaluated carefully, considering trial design, patient populations, treatment benefits, limitations, and safety outcomes.

Oncology education platforms help healthcare professionals understand these developments and consider their potential clinical implications.

For instance, the World Conference on Lung Cancer 2026 updates provide insights into emerging research involving lung cancer treatment, including biomarker-driven therapies, clinical trial findings, and evolving management strategies.

Such educational discussions can support informed professional learning and encourage clinicians to remain familiar with developments across medical oncology.

Challenges and Future Opportunities in Precision Medicine

Despite considerable progress, precision oncology still faces several challenges. Access to advanced molecular testing, treatment affordability, insurance coverage, and differences in healthcare resources can affect the availability of personalised cancer care.

Another major challenge is tumour heterogeneity. Different cancer cells within the same tumour may contain different molecular alterations. Additionally, tumours can evolve over time, potentially developing resistance to previously effective treatments.

Liquid biopsy technology is an area of ongoing research that may help address some of these challenges. By analysing circulating tumour DNA in blood samples, clinicians may obtain additional information about tumour-related genetic alterations without always requiring another tissue biopsy. Its clinical usefulness depends on the cancer type, test characteristics, and individual circumstances.

Future developments in artificial intelligence, genomic sequencing, molecular diagnostics, and combination therapies may further expand the possibilities of personalised cancer treatment.

Conclusion

Precision oncology is reshaping modern cancer care by placing greater emphasis on tumour biology, biomarker testing, and evidence-based treatment selection. Advances in targeted therapy, immunotherapy, molecular diagnostics, and clinical research are creating new opportunities for more individualised treatment strategies.